BioLineRx (BLRX) EBITDA Margin (2024 - 2026)
BioLineRx (BLRX) posted quarterly EBITDA Margin of 1745.36% for Q4 2025, down 170769.0% year-over-year from N/an in Q4 2024, and down 237.68% quarter-over-quarter from 516.86% in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) EBITDA Margin (2024 - 2026) Analysis & Trends
BioLineRx's EBITDA Margin history runs 2 years deep, the most recent figure standing at 1745.36% for Q4 2025.
- In Q4 2025, EBITDA Margin fell 170769.0% year-over-year to 1745.36%; the TTM figure through Dec 2025 stood at 871.78% (down 80126.0% YoY), while the FY2025 annual figure was 871.78%, down 80126.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 1745.36%, down from 516.86% in the prior quarter.
- The five-year high for EBITDA Margin was 37.67% in Q4 2024, with the low at 1745.36% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | BioLineRx | 6.64 Bn | 6.64 Bn | 235,000.00 | -1,215.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,215.31% |
| Mar 31, 2026 | -629.77% |
| Dec 31, 2025 | -1,745.36% |
| Sep 30, 2025 | -516.86% |
| Jun 30, 2025 | -757.57% |
| Mar 31, 2025 | -937.65% |
| Dec 31, 2024 | -37.67% |
| Sep 30, 2024 | -108.98% |
| Jun 30, 2024 | -107.05% |
| Mar 31, 2024 | -70.34% |